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INTRODUCTION  
It is generally recognized that poor solubility of drugs is one of the most frequently encountered 
difficulties in the field of formulation scheme. Low solubility and subsequent unsatisfactory dissolution 
rate often compromise oral bioavailability. 
[1] 
There are most therapeutic agents used to produce systemic 
effects by oral route that are the preferred way of administration owing to its several advantages and high 
patient compliance compared to other routes. However, poorly water-soluble drugs, when administered 
orally, have been shown to be slowly and unpredictably absorbed since their bioavailability is largely 
dependent on the dissolution process in gastrointestinal tract. 
[2] 
The bioavailability of many poorly water-
soluble drugs is limited by their dissolution rates, which are in turn controlled by the surface area that they 
present for dissolution.
 [3]
 
It is one of the major challenges to synthesize any new molecule, which is pharmacologically active for 
the researchers and pharmaceutical companies. 
[4] 
 It may be necessary to increase the dose of a poorly 
soluble drug to obtain the efficacy required.
[5]
Although pharmaceuticals have been able to overcome 
difficulties with very slightly soluble drugs, those with aqueous solubility of less than 0.1 mg/ml present 
some unique challenges. These strategies include using solubilization and surfactants, the use of 
polymorphic/ amorphic drug forms, the reduction of drug particle size, the complexation and the 
formation of solid drug dispersions. 
[6]
 
The Biopharmaceutical Classification System (BCS)  
The Biopharmaceutical classification system classifies drugs into four categories (Table 1.1), depending 
on their solubility and permeability characteristics.
 [7]
 
Parameters affecting the dissolution of Class II  
Factors important to dissolution can be identified from the following modification of the Noyes–Whitney 
equation:
 [8] 
  
 
Where  
A - Surface area of the drug  D - Diffusion coefficient of the drug  
h - Effective boundary layer thickness  
 Cs - Saturation concentration of the drug under the local gastrointestinal conditions  
V - Volume of the fluid available to dissolve the drug  
Kw/o - Water/oil partition coefficient of drug 
 [9] 
 
 
 
Table 1. 1: Physical and physiological factors important to drug dissolution 
Parameter  Physical factor  Physiological factor 
Surface area  Particle size  Native surfactants 
Diffusion coefficient  Molecular size  Viscosity of the luminal 
contents 
Boundary Layer thickness  -  Motility patterns, Flow rates 
Solubility  
 
Hydrophilicity 
Crystal structure 
 pH, buffer capacity,bile, food 
components 
Concentration of drug   -  Permeability 
Volume of GI contents  -  Secretions, Administered 
 
fluids 
TECHNIQUES FOR SOLUBILITY ENHANCEMENT 
[10] 
Liquisolid Technique 
Over the years, various techniques have been employed to enhance or retard the dissolution profile and, in 
turn, the absorption efficiency, reducing dosing frequency and bioavailability of water soluble and 
insoluble drugs and/or liquid lipophilic medications. 
[11]
 The use of water-soluble salts and polymorphic 
forms, the formation of water-soluble molecular complexes, drug micronization, solid dispersion, 
coprecipitation, lyophilization, microencapsulation, and inclusion of drug solutions or liquid drugs into 
soft gelatin capsules are some of the major formulation tools which have been shown to enhance the 
dissolution characteristics of water-insoluble drugs.
[13] 
The use of water insoluble polymers, formation of 
matrix and formation of microspheres have been shown to retardation of dissolution profile, however, 
among them, the technique of “liquisolid compacts” is one of the most promising techniques. Liquisolid 
compacts are generally considered as acceptably flowing and compressible powdered forms of liquid 
medications that implies oily liquid drugs and solutions or suspensions of water insoluble solid drugs 
carried in suitable nonvolatile solvent systems termed the liquid vehicles. Using this new formulation 
technique, a liquid medication may be converted into a dry-looking, non-adherent, free flowing and 
readily compressible powder by a simple blending with selected powder excipients referred to as the 
carrier and coating materials. Various grades of cellulose, starch, lactose, etc., may be used as the carriers, 
whereas very fine particle size silica powders may be used as the coating (or covering) materials. [14] 
Terminologies used in liquisolid technique  
i. Liquisolid compacts 
The term “Liquisolid compacts” refers to immediate or sustained release tablets or capsules that are 
prepared by process under “Liquisolid system” combined with inclusion of appropriate adjuvants required 
for tabletting or encapsulation. 
ii. Liquisolid system 
The term “Liquisolid system” refers to powdered forms of liquid medications formulated by converting 
liquid lipophilic drugs, or drug suspensions or solutions of water insoluble solid drugs in a suitable 
nonvolatile solvent, in to dry, nonadherent, free flowing and compressible powder admixtures by blending 
with selected carrier and coating material. 
iii. Liquid medication 
The term “Liquid medication” includes liquid lipophilic drugs and drug suspensions or solutions of solid 
water insoluble drugs in a suitable nonvolatile system. 
iv. Liquisolid microsystem 
The term “Liquisolid microsystem” refers to capsules prepared by the process described under “Liquisolid 
technique” combined with the inclusion of an additive, e.g. polyvinylpyrrolidone (PVP), in the liquid 
medication. 
v. Carrier material 
The term “Carrier material” refers to a preferably porous material possessing sufficient absorption 
properties, which contributes in liquid absorption.  
vi. Coating material 
The term “Coating material” refers to a material possessing fine and highly adsorptive particles, such as 
various types of which contribute in covering the wet carrier particles and displaying a dry looking 
powder by adsorbing any excess liquid. 
vii. Flowable liquid retention potential (Ф-value) 
The term “Flowable liquid retention potential” of a powder material describes its ability to retain a 
specific amount of liquid while maintaining good flow properties. The Ф-value is defined as the 
 maximum weight of liquid that can be retained per unit weight of the powder material in order to produce 
an acceptably flowing liquid/powder admixture. [15] 
Classification of Liquisolid system  
A) Based on liquid medication                         B) Based on formulation technique 
     a) Powdered drug solution                                   a) Liquisolid Compacts 
     b) Powdered drug suspension                              b) Liquisolid Microsystems 
      c) Powdered liquid drugs 
Theoretical aspects of Liquisolid technique  
In studies made by Spireas et al. in fundamental concerning flow and compression issues have been 
addressed with the use of the new formulation mathematical model of Liquisolid systems, which is based 
on the flowable (Ф-value) and compressible (Ψ -number) liquid retention potentials of the constituent 
powders. According to the above stated theories, the carrier and coating powder materials can retain only 
certain amounts of liquid while maintaining acceptable flow and compression properties. Depending on 
the excipient ratio (R) of the powder substrate given by equation 1.2, 
    R = Q/q           ---------------------------  (1.2) 
Excipient ratio (R) is the fraction of the weights of the carrier (Q) and coating (q) materials present in the 
formulation. An acceptably flowing and compressible Liquisolid system can be prepared only if a 
maximum liquid load on the carrier material is not exceeded. Such a characteristic amount of liquid is 
termed the liquid load factor (Lf) and defined as the weight ratio of the liquid medication (W) and carrier 
powder (Q) in the system, i.e.: 
    Lf = W/ Q ----------------------------             (1.3) 
The terms ‘acceptably flowing’ and ‘acceptably compressible’ imply preselected and desirable levels of 
flow and compaction which must be possessed by the final liquid: powder admixtures. Essentially, the 
acceptable flow and compaction characteristics of  this systems are ensured in a way, built in during their 
manufacturing process via the Ф-value and Ψ -number concepts [16]. 
For powder substrate consisting of a certain carrier and coating powders mixed at various powder 
excipient ratios (R), there are specific maximum liquid load factors (Lf) which must be employed in order 
to produce acceptably flowing Liquisolid systems. Such liquid load factors based upon the Ф-value and Ψ 
-number can be calculated based upon following equations, 
1) Based upon the Ф-value the optimum liquid load factor (ΦLf) can be derived by using, 
   
Φ
Lf = Ф + φ (1/R) -----------------------------             (1.4)   
Where, 
 Ф - Flowable retention potential for carrier material. φ - Flowable retention potential for coating material. 
 R - Excipient ratio. 
2) Similarly based upon the Ψ -number optimum liquid load (ΨLf) factor can be derived from, 
    
Ψ
Lf = Ψ + ψ (1/R) --------------------------------- (1.5) 
Where, 
Ψ - Compressible retention potential for carrier material. ψ - Compressible retention potential for coating material. 
R - Excipient ratio. 
For a liquid medication incorporated into a given powder substrate consisting of certain carrier and 
coating materials (e.g. microcrystalline cellulose and silica) blended at a specific excipient ratio (R), there 
exists an optimum liquid load factor, L0, required to produce acceptably flowing and, simultaneously, 
acceptably compressible Liquisolid preparations. The LO value required at a given powder excipient ratio 
for any system is equal to either its 
Φ
Lf or 
Ψ
Lf value, whichever is less; thus: 
  LO  =  
Φ
Lf    When, 
Φ
Lf < 
Ψ
LΦf     -----------------     (1.6) 
    Or 
                       LO  =  
Ψ
Lf   When, 
Φ
Lf  >
Ψ
Lf          -----------------     (1.7) 
 Optimum liquid load factor of a given excipient ratio system is established, the appropriate quantities of 
carrier (Q0) and coating (q0) powder materials required to convert a given amount of liquid medication 
(W) into an acceptably flowing and compressible Liquisolid system, may be calculated as follows: 
    Q0 = W/ L0 -------------------------------------   (1.8) 
        Q0 = Q0/R  -------------------------------------   (1.9) 
The minimum carrier quantity (Qmin) and maximum coating quantity (qmax) required to produce an 
acceptably flowing and compressible Liquisolid compacts unit possessing minimum weight (Umin) and 
containing W of liquid may assessed using following relation,  
    Qmin = W/Lmax  -----------------------------  (1.10)    
    qmax = Qmin/ Rmin -----------------------------  (1.11) 
In terms of producing compacts of realistic unit size, the practical substance of the Liquisolid formulation 
desired to be prepared may be assessed by predicting unit dose weight Uw using equation 1.10. This can 
be done as long as weight W of the liquid medication (to be included in a single Liquisolid formulation) 
and the desired excipient ratio (R) of the formulation have been selected leading to the determination of 
the required optimum load factor (L0). The minimum possible unit dose weight (Umin) which can be 
produced by the carrier: coating system may also be predicted using equation 1.10, having selected the 
weight W of the liquid medication (per unit dose) and having determined the minimum excipient ratio 
(Rmin) of the powder system and its corresponding maximum load factor Lmax required to yield a Flowable 
and compressible Liquisolid system. 
[17]
  
Uw = W + W (1+ 1/R) (LO)         ----------------------------           (1.11)  
 Umin = W +W (1+ 1/Rmin) (1/ Lmax)                     ----------------------------           (1.12) 
Powdered solution technology 
A more recent technique, entitled “powdered solution technology”, has been applied to prepare water soluble or 
water insoluble drugs into rapid release or sustained release solid dosage forms. The concept of powdered solutions 
enables one to convert drug solutions or liquid drugs into acceptably flowing powders by a simple admixture with 
selected powder excipients. 
[18]
 
Method of Preparation of Liquisolid system  
The preparation of Liquisolid system is based on equations no. 1.2 to 1.13.  
i. Selection and preparation of drug solution: If a solid water-insoluble drug is formulated, the drug is dissolved or 
suspended in a non-volatile solvent or vehicle.(% w/w concentration).  
ii. Selection of Carrier and Coating materials: The carrier and coating materials to be incorporated in the Liquisolid 
formulation are selected on the basis of, the characteristic excipient or carrier: coating ratio Rmin (w/w) and the 
Flowable liquid retention potential (Ф-value) and compressible liquid retention potential (Ψ -number) are 
determined by using Liquisolid flowability test (LSF) and Liquisolid compressibility test (LSC) respectively. 
iii. The desired excipient or carrier: coating ratio R, where R>Rmin, of the carrier: coating combination to be included in 
the liquisolid system is selected. If minimum unit dose weight (Umin) is desired, the excipient ratio of the 
formulation must be selected to be equal to Rmin which is the characteristic minimum excipient ratio of the carrier: 
coating system used.  
iv. Selected amounts (W) of the resulting hot liquid medications were incorporated into calculated quantities of carrier 
and coating materials. 
v. Determination of Liquid load factor: The optimum liquid load factor (LO) required yielding an acceptable 
flowing and compressible Liquisolid system is assessed by using equation 1.9-1.12.
[19]
 
Mixing process  
The mixing procedure was conducted in three 
stages. During the first stage, the system was 
blended at an approximate mixing rate of one 
rpm in order to consistently distribute the 
liquid medication into the powder. In the 
second stage, the liquid/powder admixture was 
 
 
 
  
             
 
 
 
 
          
                                                                       
Mechanism involved in designing of Liquisolid system 
                                                                                       
 
  
 
 
Advantages of Liquisolid technique 
[22] 
1. A great number of slightly and very slightly water soluble and practically water insoluble drugs can be 
formulated in to Liquisolid system. Production cost of Liquisolid system is lower than that of soft gelatin 
capsule, as production of Liquisolid system is similar to that of conventional tablets. 
2. Optimized sustained release Liquisolid tablets or capsules of water-insoluble drugs reveal surprisingly 
constant dissolution rates compared to conventional expensive tablets. 
Complexation  
 Inclusion complexes are formed by the insertion of the nonpolar region of one molecule into the cavity of 
molecule or group of molecule. Cyclodextrins (CDs) used as complexation agents. The natural and most 
employed cyclodextrins are crystalline, homogeneous, non-hygroscopic substances. They are 
biocompatible, non-toxic in a wide range of concentration, relatively inexpensive and produced naturally 
 
Liquisolid hypothesis that, if a liquid is 
incorporated into a material which has a 
porous surface and closely matted fibers 
in its interior, e.g., cellulose, both 
absorption and adsorption take place. 
The liquid is initially absorbed in the 
interior of the particles by its internal 
structure and after the saturation of 
process, adsorption of the liquid onto 
the internal and external surfaces of the 
porous carrier particle occurs. It 
represents the generalized “total liquid 
retention potential” or “holding 
capacity” of the sorbent. The coating 
material, which possesses high 
adsorptive properties and large specific 
surface area, gives the Liquisolid system 
the desirable flow characteristics. [21] 
 
 Figure 1.2: Mechanism representing formulation 
of liquisolid system 
Fi gure 1.1: Method of preparation of 
liquisolid    compacts                                                
 by enzyme degradation of starch.
 [23]
The most notable feature of cyclodextrins is their ability to form solid 
inclusion complexes. Complex formation is a dimensional fit between host cavity and guest molecule. 
The lipophilic cavity of cyclodextrin molecules provides a microenvironment into which appropriately 
sized non-polar moieties can enter to form inclusion complexes. No covalent bonds are broken or formed 
during formation of the inclusion complex. 
[24]
 
Kneading method       
It is one of the methods used in formation of complex between drug and β- cyclodextrin. [25]  
Synergism effect 
Synergistic effect of nonvolatile solvents like PEG-400 and cyclodextrin may have effect on the solubility 
of drug. Beta cyclodextrin was used as a type of cyclodextrins.
 
PEG-400 used in an attempt to improve 
the aqueous solubility of drug. The aqueous solubility of a drug improved significantly by the addition of 
PEG-400 and β- cyclodextrin. The theoretical solubility was calculated by adding the solubilities in the 
individual systems. The observed solubility value was higher than the theoretical values. The effect of 
synergism was significant in 5% to 50% PEG-400 containing beta cyclodextrin. 
[26] 
BIOAVAILABILITY 
Bioavailability is defined as the rate and extent (amount) of absorption of unchanged drug from its dosage 
form. It is one of the important parameter to achieve desired concentration of drug in systemic circulation 
for pharmacological response to be shown. A drug with poor bioavailability is one with poor aqueous 
solubility, slow dissolution rate in biological fluids, poor stability of dissolved drug at physiological pH, 
poor permeation through biomembrane, extensive presystemic metabolism. Poorly water soluble drugs 
often require high doses in order to reach therapeutic plasma concentrations after oral administration. Low 
aqueous solubility is the major problem encountered with formulation development of new chemical 
entities. 
[27] 
Techniques for improving bioavailability 
There are various techniques available to improve the solubility of poorly soluble drugs. Some of the 
methods to improve the solubility includes Physical modifications Chemical Modifications formulation 
based  novel drug delivery system and inhibition of P-glycoprotein efflux. Inhibition of P-glycoprotein 
efflux by using P-glycoprotein inhibitors, surfactants, dendrimers.
 [28]
To improve the systemic availability 
of the drug is to deliver it by alternative routes of administration such as parenteral, nasal, vaginal, rectal 
or transdermal. However, improvement of the oral bioavailability of the drug is the most realistic 
approach, as it is the most preferred and convenient route of administration. 
[29]
  
FORMULATION OF LIQUISOLID SYSTEM 
[30]
 
Preparation of complex with beta cyclodextrin Kneading method   
Preparation of complex of drug with beta cyclodextrin done by:  
First the cyclodextrin is added to the mortar; further small quantity of 50% ethanol is added while 
triturating to get slurry like consistency. Then slowly drug is incorporated into the slurry and trituration is 
further continued for 30 minutes. Slurry is then air dried at 25
0
C for 1 hrs, pulverized and passed through 
sieve No. 80 and stored.  
Solubility studies of complex and synergism effect with different ratios   
The complex of drug and beta cyclodextrin Complex was taken in different mass ratios. after that 
complex was taken in liquid vehicle for studying the synergism effect. 
Determination of angle of slide for various excipients  
10 gram of powder excipients were weighed accurately and placed at one end of an aluminum metal plate 
with a polished surface. This end was raised gradually until the plate made an angle with the horizontal at 
which the powder was about to slide. This angle θ represented the angle of slide. It was taken as a 
measure for the flow characters of powders. An angle of slide corresponding to 33
0 
corresponded to 
optimal flow properties. 
 PRECOMPRESSION STUDY
 [31]
 
Flow properties of the Liquisolid system  
Flow properties of the Liquisolid systems were estimated by determining the angle of repose, Carr’s 
Compressibility index (CCI), and Hausner’s ratio (HR). Angle of repose was measured according to the 
fixed funnel and free standing cone method. A funnel with the end of the stem cut perpendicular to the 
axis of symmetry is secured with its tip 2 cm height, H, above a graph paper placed on a flat horizontal 
surface. The powders were carefully poured through the funnel until the apex of the conical pile so 
formed just reaches the tip of the funnel. The radius of heap was calculated and tangent of the angle of 
repose was given by: 
                                                        θ= tan-1(H/R)                ------------------                           (6.9) 
Where, θ is the angle of repose, H is height of pile and R is radius of pile. 
The Bulk density and Tap densities were determined for the calculation of Hausner’s ratio (HR) and 
Carr’s Compressibility Index. (CCI).It was determined by following equation,  
                                                
 TD - BD
CCI = 100
TD
  -------------------              (6.10)         
                         TDHR=
BD
 
 
 
 ------------------              (6.12)                                  
Where, TD and BD are tapped density and bulk density respectively.  
POST COMPRESSION STUDY 
[32]
  
Evaluation of liquisolid compacts  
Weight variation test 
[33]
 
Twenty tablets from each formulation were selected at random and average weight was determined. Then 
the individual tablets were weighed and were compared with average weight. Not more than 2 of 
individual weight deviate by more than percentage (refer table 1.2), while none deviates by more than 
twice that percentage. 
                                    Table 1.2: Uniformity of weight 
Dosage form Average weight % deviation 
Uncoated and film coated tablets 
80 mg or less 10 
> 80mg and less than 250 mg 7.5 
250 mg or more 5 
Hardness test 
[34]
 
After preparation of matrices, primary micromeritic properties are measured like, Tablet thickness, 
diameter, weight & hardness. Thickness & diameter is measured by using varnier caliper, hardness is 
determined by using Monsanto hardness tester. Tablet hardness is defined as the force required breaking a 
tablet in a diametric compression force. It is also known as tablet crushing strength. The hardness tester 
used in the study was Monsanto Hardness Tester, which applies the force to the tablet diametrically with 
the help of an in built spring. The tester was initially adjusted to zero.  
Diameter and thickness 
Diameter and thickness was performed by using digital vernier caliper. Results for all the batches of 
liquisolid compacts were reported. 
Friability test
[35]
 
 Friability test is performed to assess the effect of friction and shock that may often cause tablet to chip, 
cap, or break. Friabilator was used for the purpose. Compressed tablets should not lose more than 1% of 
their weight. It is the phenomenon whereby tablet surfaces are damaged and/or show evidence of 
lamination or breakage when subjected to mechanical shock or attrition. The friability of tablets was 
determined by using Friabilator. It is expressed in percentage (%). Ten tablets were initially weighed 
 (Winitial) and transferred into Friabilator. The Friabilator was operated at 25 rpm for 4 minutes or run up to 
100 revolutions. The tablets were weighed again (Wfinal). The percentage friability was then calculated by,  
                                            
               
        
                   ------------------  (6.13)                                     
In vitro dissolution study 
[36]
 
The various compacts were subjected to dissolution test using USP Type II Apparatus.  
Differential Scanning Calorimetry (DSC)
 [37]
 
Thermograms of the samples were recorded on a DSC.Thermal behavior of the samples was investigated 
under a scanning rate of 10°C/min, covering a temperature range of 30–300°C. 
Powder-X Ray Diffraction (P-XRD)
 
X-ray diffractograms of liquisolid formulations were performed by using Philips Analytical. The cross 
section of samples was exposed to X-ray radiation. 
FTIR Study  
FTIR is an important tool to analyze the purity of the drug. FTIR spectrum shows the fundamental peaks 
corresponding to the chemical nature of the drug and excipients. FTIR studies were carried out in order to 
determine any possible interaction among drug and other excipients; it was carries out by FTIR 
spectrophotometer.  
IN VIVO STUDIES 
In-vivo studies of solid formulations
 [38]
 
Bioavailability studies of prepared solid formulations 
The bioavailability studies were performed for the prepared formulation containing herbal inibitors like 
piperine. Female rabbit was selected as experimental model having weight 1.5 to 2.5 kg. The blood serum 
concentration of drug was determined along with AUC, Cmax, and Tmax. 
Experimental layout 
Study Protocol 
Healthy adult albino rabbits were used for the study of pharmacokinetic parameter and were divided into 
4 groups namely control, test 1, test 2 and standard. Animals were used repeatedly by keeping washout 
period for complete removal of drug from body. All animals were taken care of under ethical 
consideration as per the guidelines.  
                                                                                                              
 
52 
A 
B 
Drug administration and sampling 
The animals were required to be kept on 
standard supplemented diet and water for one 
week prior to experiment and maintained on it 
thereafter. For study, albino rabbits were 
randomly assigned to four groups on body 
weight basis. Group 1 was serve as normal 
control (water), Group 2 was serve as positive 
control (standard drug), group 3 and 4 was 
treated with the liquisolid formulation and 
experiment was repeated for study by keeping 
washout period between of 8 days. The steps 
involved in drug administration and sampling as, 
 
 Figure 1.3: Process flow of bioavailability 
   
                                                                        study by taking rabbit as model 
Procedure for animal experimental work 
 
         Figure 1.4: Blood sample collection 
                                                                                       of rabbit  by ear marginal vein puncture 
Blood sample processing 
1. The collected blood sample was processed through centrifugation at 5000 rpm for 15 min. 
2. Supernatant clear serum sample was separated with the help of micropipette in graduated plastic tube 
having cap. 
3. The volume of serum sample was further diluted up to 1 ml with optimized mobile phase i.e. methanol: 
water (80:20 v/v). 
4. Precipitation of proteins was separated by again centrifugation with 5000 rpm for 15 min. The obtained 
supernatant was separated with the help of micropipette. 
5. The clear supernatant was again filtered with 0.42 micron Whatmann syringe filter and finally used the 
HPLC analysis using DAD detector. 
STABILITY STUDY 
[39]
 
Stability testing of drug products begins as a part of drug discovery and ends with the demise of the 
compound or commercial product. FDA and ICH specifies the guidelines for stability testing of new drug 
products, as a technical requirement for the registration of pharmaceuticals for human use. The 
formulation were wrapped in aluminum foil, and then placed in umber colored bottle.  
CONCLUSION 
Liquisolid technique can be optimized for the production of immediate release of drug. Simplicity, low 
cost and capability of industrial production are some of the advantages of this technique. The complex of 
drug and beta cyclodextrin was successfully prepared by   kneading method. Complex was taken which 
shows synergetic effect and enhances solubility drug. The results showed that maximum drug can be 
incorporated with dissolution enhancement compared with conventional formulation. Hence, this 
liquisolid technique with two way approach of solubility and bioavailability enhancement may found as 
key aspect in oral formulations. Liquisolid technique can successfully be employed to enhance the 
solubility and dissolution properties. 
 
The parameters were selected for the 
experimental work: 
The sample for dose was prepared with gum 
acacia suspension for required animal dose. 
Prepared solid formulation of physical mixture 
was administered as a single oral dose to rabbit 
through oral feeding needle and 2 ml of water 
was again given over the dose. 
The blood sample of rabbit was collected via ear 
marginal vein puncture, for that 1ml insulin 
syringe was used. 1 ml blood sample was 
collected while in each withdrwal. 
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